Jameela A Jackson, | |
6701 Highway 67, Benton, AR 72015-8909 | |
(501) 303-3105 | |
Not Available |
Full Name | Jameela A Jackson |
---|---|
Gender | Female |
Speciality | Counselor - Professional |
Location | 6701 Highway 67, Benton, Arkansas |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1760781439 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Jameela A Jackson, 6701 Highway 67 Bldg 4, Benton, AR 72015-8909 Ph: (501) 821-5500 | Jameela A Jackson, 6701 Highway 67, Benton, AR 72015-8909 Ph: (501) 303-3105 |
News Archive
A pay-for-performance program in electronic-health-records-(EHR)-enabled small practices led to modest improvements in cardiovascular care processes and outcomes, according to a study in the September 11 issue of JAMA.
Liquent, Inc. today announced it has entered into a strategic partnership with eSA, Inc., a leading solutions provider for regulatory information management and regulatory services within Asia. Through an exclusive agreement, eSA will now have the commercial and technical support responsibilities for Liquent's strategic offerings, Liquent InSight and Liquent SmartDesk.
Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.
In what researchers are calling a game changer for future ataxia treatments, a new study showed the ability to turn down the disease progression of the most common dominantly inherited ataxia.
› Verified 4 days ago